Modality
ADC
MOA
CDK4/6i
Target
TNFα
Pathway
Notch
AngelmanPAHEndometrial Ca
Development Pipeline
Preclinical
Aug 2017
→ Aug 2029
PreclinicalCurrent
NCT04601716
851 pts·Endometrial Ca
2017-08→2029-08·Completed
851 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-163.4y awayInterim· Endometrial Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2029-08-16 · 3.4y away
Endometrial Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04601716 | Preclinical | Endometrial Ca | Completed | 851 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| MRN-8225 | Moderna | Preclinical | TNFα |